Carole E Aubert1, Carmen Floriani1, Douglas C Bauer2, Bruno R da Costa3,4, Daniel Segna1, Manuel R Blum1, Tinh-Hai Collet5, Howard A Fink6,7, Anne R Cappola8, Lamprini Syrogiannouli3, Robin P Peeters9, Bjørn O Åsvold10,11, Wendy P J den Elzen12, Robert N Luben13, Alexandra P Bremner14, Apostolos Gogakos15, Richard Eastell16, Patricia M Kearney17, Mari Hoff10,18, Erin Le Blanc19, Graziano Ceresini20, Fernando Rivadeneira9, André G Uitterlinden9, Kay-Tee Khaw14, Arnulf Langhammer10, David J Stott21, Rudi G J Westendorp22, Luigi Ferrucci23, Graham R Williams16, Jacobijn Gussekloo12,24, John P Walsh25,26, Drahomir Aujesky1, Nicolas Rodondi1,3. 1. Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. 2. Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, California 94143. 3. Institute of Primary Health Care (Berner Institut für Hausarztmedizin), University of Bern, 3012 Bern, Switzerland. 4. Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, 3010 Bern, Switzerland. 5. Service of Endocrinology, Diabetes, and Metabolism, University Hospital of Lausanne, 1011 Lausanne, Switzerland. 6. Geriatric Research Education and Clinical Center, Veterans Affairs Health Care System, Minneapolis, Minnesota 55417. 7. Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455. 8. University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104. 9. Departments of Internal Medicine and Epidemiology, Erasmus University Rotterdam, 3062 Rotterdam, The Netherlands. 10. Department of Public Health and Nursing, Norges teknisk-naturvitenskapelige universitet, Norwegian University of Science and Technology, N-7491 Trondheim, Norway. 11. Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, N-7006 Trondheim, Norway. 12. Leiden University Medical Center, Department of Clinical Chemistry and Laboratory Medicine, 2300 RC Leiden, The Netherlands. 13. Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0SR, United Kingdom. 14. School of Population Health, University of Western Australia, Crawley, Perth, Western Australia 6009, Australia. 15. Molecular Endocrinology Laboratory, Hammersmith Campus, Department of Medicine, Imperial College London, London W12 0NN, United Kingdom. 16. Department of Oncology and Metabolism, University of Sheffield, Sheffield, South Yorkshire S10 2TN, United Kingdom. 17. Department of Epidemiology and Public Health, University College Cork, T12 PX46 Cork, Ireland. 18. Levanger Hospital, Nord-Trøndelag Hospital Trust, 7600 Levanger, Norway. 19. Center for Health Research NW, Kaiser Permanente, Portland, Oregon 97277. 20. Department of Clinical and Experimental Medicine, Geriatric Endocrine Unit, University Hospital of Parma, 43126 Parma, Italy. 21. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G31 2ER, United Kingdom. 22. Department of Public Health, Center for Health Aging, University of Copenhagen, 1004 Copenhagen, Denmark. 23. National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224. 24. Department of Gerontology and Geriatrics, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands. 25. Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia. 26. School of Medicine and Pharmacology, University of Western Australia, Crawley, Perth, Western Australia 6009, Australia.
Abstract
Context: Hyperthyroidism is associated with increased fracture risk, but it is not clear if lower thyroid-stimulating hormone (TSH) and higher free thyroxine (FT4) in euthyroid individuals are associated with fracture risk. Objective: To evaluate the association of TSH and FT4 with incident fractures in euthyroid individuals. Design: Individual participant data analysis. Setting: Thirteen prospective cohort studies with baseline examinations between 1981 and 2002. Participants: Adults with baseline TSH 0.45 to 4.49 mIU/L. Main Outcome Measures: Primary outcome was incident hip fracture. Secondary outcomes were any, nonvertebral, and vertebral fractures. Results were presented as hazard ratios (HRs) with 95% confidence interval (CI) adjusted for age and sex. For clinical relevance, we studied TSH according to five categories: 0.45 to 0.99 mIU/L; 1.00 to 1.49 mIU/L; 1.50 to 2.49 mIU/L; 2.50 to 3.49 mIU/L; and 3.50 to 4.49 mIU/L (reference). FT4 was assessed as study-specific standard deviation increase, because assays varied between cohorts. Results: During 659,059 person-years, 2,565 out of 56,835 participants had hip fracture (4.5%; 12 studies with data on hip fracture). The pooled adjusted HR (95% CI) for hip fracture was 1.25 (1.05 to 1.49) for TSH 0.45 to 0.99 mIU/L, 1.19 (1.01 to 1.41) for TSH 1.00 to 1.49 mIU/L, 1.09 (0.93 to 1.28) for TSH 1.50 to 2.49 mIU/L, and 1.12 (0.94 to 1.33) for TSH 2.50 to 3.49 mIU/L (P for trend = 0.004). Hip fracture was also associated with FT4 [HR (95% CI) 1.22 (1.11 to 1.35) per one standard deviation increase in FT4]. FT4 only was associated with any and nonvertebral fractures. Results remained similar in sensitivity analyses. Conclusions: Among euthyroid adults, lower TSH and higher FT4 are associated with an increased risk of hip fracture. These findings may help refine the definition of optimal ranges of thyroid function tests.
Context:Hyperthyroidism is associated with increased fracture risk, but it is not clear if lower thyroid-stimulating hormone (TSH) and higher free thyroxine (FT4) in euthyroid individuals are associated with fracture risk. Objective: To evaluate the association of TSH and FT4 with incident fractures in euthyroid individuals. Design: Individual participant data analysis. Setting: Thirteen prospective cohort studies with baseline examinations between 1981 and 2002. Participants: Adults with baseline TSH 0.45 to 4.49 mIU/L. Main Outcome Measures: Primary outcome was incident hip fracture. Secondary outcomes were any, nonvertebral, and vertebral fractures. Results were presented as hazard ratios (HRs) with 95% confidence interval (CI) adjusted for age and sex. For clinical relevance, we studied TSH according to five categories: 0.45 to 0.99 mIU/L; 1.00 to 1.49 mIU/L; 1.50 to 2.49 mIU/L; 2.50 to 3.49 mIU/L; and 3.50 to 4.49 mIU/L (reference). FT4 was assessed as study-specific standard deviation increase, because assays varied between cohorts. Results: During 659,059 person-years, 2,565 out of 56,835 participants had hip fracture (4.5%; 12 studies with data on hip fracture). The pooled adjusted HR (95% CI) for hip fracture was 1.25 (1.05 to 1.49) for TSH 0.45 to 0.99 mIU/L, 1.19 (1.01 to 1.41) for TSH 1.00 to 1.49 mIU/L, 1.09 (0.93 to 1.28) for TSH 1.50 to 2.49 mIU/L, and 1.12 (0.94 to 1.33) for TSH 2.50 to 3.49 mIU/L (P for trend = 0.004). Hip fracture was also associated with FT4 [HR (95% CI) 1.22 (1.11 to 1.35) per one standard deviation increase in FT4]. FT4 only was associated with any and nonvertebral fractures. Results remained similar in sensitivity analyses. Conclusions: Among euthyroid adults, lower TSH and higher FT4 are associated with an increased risk of hip fracture. These findings may help refine the definition of optimal ranges of thyroid function tests.
Authors: J H Duncan Bassett; Alan Boyde; Peter G T Howell; Richard H Bassett; Thomas M Galliford; Marta Archanco; Holly Evans; Michelle A Lawson; Peter Croucher; Donald L St Germain; Valerie Anne Galton; Graham R Williams Journal: Proc Natl Acad Sci U S A Date: 2010-04-05 Impact factor: 11.205
Authors: John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli Journal: Arch Intern Med Date: 2005-11-28
Authors: Michael D Brennan; Claudia Powell; Kenton R Kaufman; Pi Chang Sun; Rebecca S Bahn; K Sreekumaran Nair Journal: Thyroid Date: 2006-04 Impact factor: 6.568
Authors: Bu B Yeap; Helman Alfonso; S A Paul Chubb; Gaurav Puri; Graeme J Hankey; Leon Flicker; Osvaldo P Almeida Journal: J Clin Endocrinol Metab Date: 2012-09-13 Impact factor: 5.958
Authors: Judith Finigan; Diana M Greenfield; Aubrey Blumsohn; Rosemary A Hannon; Nicola F Peel; Guirong Jiang; Richard Eastell Journal: J Bone Miner Res Date: 2008-01 Impact factor: 6.741
Authors: Graziano Ceresini; Gian Paolo Ceda; Fulvio Lauretani; Marcello Maggio; Elisa Usberti; Michela Marina; Stefania Bandinelli; Jack M Guralnik; Giorgio Valenti; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2013-05-06 Impact factor: 7.538
Authors: Reed A Siemieniuk; Thomas Agoritsas; Veena Manja; Tahira Devji; Yaping Chang; Malgorzata M Bala; Lehana Thabane; Gordon H Guyatt Journal: BMJ Date: 2016-09-28
Authors: Aline S da S Correia; Michele L F Nascimento; Letícia B B de M Teixeira; Silvana O E Silva; Mário Vaisman; Patricia F S Teixeira Journal: Eur Geriatr Med Date: 2021-11-24 Impact factor: 1.710
Authors: Rosalie B T M Sterenborg; Tessel E Galesloot; Alexander Teumer; Romana T Netea-Maier; Doug Speed; Marcel E Meima; W Edward Visser; Johannes W A Smit; Robin P Peeters; Marco Medici Journal: J Clin Endocrinol Metab Date: 2022-05-17 Impact factor: 6.134